PMID- 28238095
OWN - NLM
STAT- MEDLINE
DCOM- 20170418
LR  - 20170418
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 96
IP  - 5
DP  - 2017 May
TI  - ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell 
      adhesion-mediated drug resistance (CAM-DR).
PG  - 847-858
LID - 10.1007/s00277-017-2949-2 [doi]
AB  - Cell adhesion-mediated drug resistance (CAM-DR) remains the primary obstacle in 
      human multiple myeloma (MM) therapy. In this study, we aimed at investigating the 
      expression and biologic function of ARF1 in MM. We determined that ARF1 
      expression was positively correlated with cell proliferation and knockdown of 
      ARF1 contributed to CAM-DR. The enhancement in the adhesion of MM cells to 
      fibronectin (FN) or the bone marrow stroma cell line HS-5 cells translated to an 
      increased CAM-DR phenotype. Importantly, we showed that this CAM-DR phenotype was 
      correlated with the phosphorylation of Akt and ERK in MM cells. Moreover, we 
      sought to determine whether ARF1 could interact with p27 in RPMI8226 cells. 
      Knockdown of ARF1 also significantly decreased pT157-p27 protein expression in 
      RPMI8226 cells. Our research shows ARF1 may reverse CAM-DR by regulating 
      phosphorylation of p27 at T157 in MM. Taken together, our data shed new light on 
      the molecular mechanism of CAM-DR in MM, and targeting ARF1 may be a novel 
      therapeutic approach for improving the effectiveness of chemotherapy in MM.
FAU - Xu, Xiaohong
AU  - Xu X
AD  - Department of Oncology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, Jiangsu, People's Republic of China.
FAU - Wang, Qiru
AU  - Wang Q
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Medical College, Nantong University, Nantong, 226001, Jiangsu Province, People's 
      Republic of China.
FAU - He, Yunhua
AU  - He Y
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Medical College, Nantong University, Nantong, 226001, Jiangsu Province, People's 
      Republic of China.
FAU - Ding, Linlin
AU  - Ding L
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Medical College, Nantong University, Nantong, 226001, Jiangsu Province, People's 
      Republic of China.
FAU - Zhong, Fei
AU  - Zhong F
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Medical College, Nantong University, Nantong, 226001, Jiangsu Province, People's 
      Republic of China.
FAU - Ou, Yangyu
AU  - Ou Y
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Medical College, Nantong University, Nantong, 226001, Jiangsu Province, People's 
      Republic of China.
FAU - Shen, Yaodong
AU  - Shen Y
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Medical College, Nantong University, Nantong, 226001, Jiangsu Province, People's 
      Republic of China.
FAU - Liu, Hong
AU  - Liu H
AD  - Department of Hematology, Affiliated Hospital of Nantong University, Nantong 
      University, Nantong, 22600, Jiangsu Province, People's Republic of China. 
      hongliu63@163.com.
AD  - Department of Hematology, Affiliated Hospital of Nantong University, Nantong 
      University, 19 Qixiu Road, Nantong, Jiangsu, 226361, China. hongliu63@163.com.
FAU - He, Song
AU  - He S
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 30 
      North Tongyang Road, Pingchao, Nantong, 226361, Jiangsu, People's Republic of 
      China. ntzlyyhesong515@ntu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20170225
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (Biomarkers)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
RN  - EC 3.6.5.2 (ADP-Ribosylation Factor 1)
SB  - IM
MH  - ADP-Ribosylation Factor 1/*genetics/metabolism
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers
MH  - Cell Adhesion/*genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Cyclin-Dependent Kinase Inhibitor p27/metabolism
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Gene Expression
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Gene Silencing
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/drug therapy/*genetics/mortality
MH  - Phosphorylation
MH  - Proportional Hazards Models
MH  - RNA Interference
MH  - Signal Transduction
MH  - Treatment Outcome
OTO - NOTNLM
OT  - ARF1
OT  - CAM-DR
OT  - Multiple myeloma
OT  - Proliferation
OT  - p27
EDAT- 2017/02/27 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/02/27 06:00
PHST- 2016/03/15 00:00 [received]
PHST- 2017/02/10 00:00 [accepted]
PHST- 2017/02/27 06:00 [pubmed]
PHST- 2017/04/19 06:00 [medline]
PHST- 2017/02/27 06:00 [entrez]
AID - 10.1007/s00277-017-2949-2 [pii]
AID - 10.1007/s00277-017-2949-2 [doi]
PST - ppublish
SO  - Ann Hematol. 2017 May;96(5):847-858. doi: 10.1007/s00277-017-2949-2. Epub 2017 
      Feb 25.